Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

Cited In for PubMed (Select 10859303)

1.

Dual Effect of Chrysanthemum indicum Extract to Stimulate Osteoblast Differentiation and Inhibit Osteoclast Formation and Resorption In Vitro.

Baek JM, Kim JY, Cheon YH, Park SH, Ahn SJ, Yoon KH, Oh J, Lee MS.

Evid Based Complement Alternat Med. 2014;2014:176049. doi: 10.1155/2014/176049. Epub 2014 Oct 28.

2.

Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells.

Kong L, Zhao Q, Wang X, Zhu J, Hao D, Yang C.

BMC Complement Altern Med. 2014 Dec 12;14:481. doi: 10.1186/1472-6882-14-481.

3.

Fucoidan, a sulfated polysaccharide, inhibits osteoclast differentiation and function by modulating RANKL signaling.

Kim YW, Baek SH, Lee SH, Kim TH, Kim SY.

Int J Mol Sci. 2014 Oct 20;15(10):18840-55. doi: 10.3390/ijms151018840.

4.

The study of mechanisms of protective effect of Rg1 against arthritis by inhibiting osteoclast differentiation and maturation in CIA mice.

Gu Y, Fan W, Yin G.

Mediators Inflamm. 2014;2014:305071. doi: 10.1155/2014/305071. Epub 2014 Aug 21.

5.

TRP14 inhibits osteoclast differentiation via its catalytic activity.

Hong S, Huh JE, Lee SY, Shim JK, Rhee SG, Jeong W.

Mol Cell Biol. 2014 Sep 15;34(18):3515-24. doi: 10.1128/MCB.00293-14. Epub 2014 Jul 7.

6.

Interactomics profiling of the negative regulatory function of carbon monoxide on RANKL-treated RAW 264.7 cells during osteoclastogenesis.

Tseng FJ, Chia WT, Shyu JF, Gou GH, Sytwu HK, Hsia CW, Tseng MJ, Pan RY.

BMC Syst Biol. 2014 May 18;8:57. doi: 10.1186/1752-0509-8-57.

7.

Counter-regulation of T cell effector function by differentially activated p38.

Alam MS, Gaida MM, Ogawa Y, Kolios AG, Lasitschka F, Ashwell JD.

J Exp Med. 2014 Jun 2;211(6):1257-70. doi: 10.1084/jem.20131917. Epub 2014 May 26.

8.

Anti-osteoclastogenic activity of praeruptorin A via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLCγ-independent Ca2+ oscillation.

Yeon JT, Kim KJ, Choi SW, Moon SH, Park YS, Ryu BJ, Oh J, Kim MS, Erkhembaatar M, Son YJ, Kim SH.

PLoS One. 2014 Feb 21;9(2):e88974. doi: 10.1371/journal.pone.0088974. eCollection 2014.

9.

Treatment with Rhizoma Dioscoreae extract has protective effect on osteopenia in ovariectomized rats.

Zhang Z, Xiang L, Bai D, Fu X, Wang W, Li Y, Liu H, Pan J, Li Y, Xiao GG, Ju D.

ScientificWorldJournal. 2014 Jan 9;2014:645975. doi: 10.1155/2014/645975. eCollection 2014.

10.

Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.

Yamashita T, Uehara S, Udagawa N, Li F, Kadota S, Esumi H, Kobayashi Y, Takahashi N.

PLoS One. 2014 Jan 17;9(1):e85878. doi: 10.1371/journal.pone.0085878. eCollection 2014.

11.

Differential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss.

Boyle DL, Hammaker D, Edgar M, Zaiss MM, Teufel S, David JP, Schett G, Firestein GS.

PLoS One. 2014 Jan 6;9(1):e84818. doi: 10.1371/journal.pone.0084818. eCollection 2014. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/4fbfa4f0-cb27-4ec4-80d6-3b0ed5e9e8b8.

13.

Sinomenine suppresses osteoclast formation and Mycobacterium tuberculosis H37Ra-induced bone loss by modulating RANKL signaling pathways.

Li X, He L, Hu Y, Duan H, Li X, Tan S, Zou M, Gu C, Zeng X, Yu L, Xu J, Liu S.

PLoS One. 2013 Sep 16;8(9):e74274. doi: 10.1371/journal.pone.0074274. eCollection 2013.

14.

Selective induction of P2Y14 receptor by RANKL promotes osteoclast formation.

Lee SA, Park JH, Lee SY.

Mol Cells. 2013 Sep;36(3):273-7. doi: 10.1007/s10059-013-0226-3. Epub 2013 Sep 17.

15.

The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.

Kogawa M, Hisatake K, Atkins GJ, Findlay DM, Enoki Y, Sato T, Gray PC, Kanesaki-Yatsuka Y, Anderson PH, Wada S, Kato N, Fukuda A, Katayama S, Tsujimoto M, Yoda T, Suda T, Okazaki Y, Matsumoto M.

J Biol Chem. 2013 Oct 25;288(43):31299-312. doi: 10.1074/jbc.M113.461848. Epub 2013 Aug 29.

16.

The polyphenol fisetin protects bone by repressing NF-κB and MKP-1-dependent signaling pathways in osteoclasts.

Léotoing L, Wauquier F, Guicheux J, Miot-Noirault E, Wittrant Y, Coxam V.

PLoS One. 2013 Jul 4;8(7):e68388. doi: 10.1371/journal.pone.0068388. Print 2013.

17.

Effects and interaction of icariin, curculigoside, and berberine in er-xian decoction, a traditional chinese medicinal formula, on osteoclastic bone resorption.

Xue L, Jiao L, Wang Y, Nie Y, Han T, Jiang Y, Rahman K, Zhang Q, Qin L.

Evid Based Complement Alternat Med. 2012;2012:490843. doi: 10.1155/2012/490843. Epub 2012 Nov 1.

18.

TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis.

Lamothe B, Lai Y, Xie M, Schneider MD, Darnay BG.

Mol Cell Biol. 2013 Feb;33(3):582-95. doi: 10.1128/MCB.01225-12. Epub 2012 Nov 19.

19.

Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells.

Kavitha CV, Deep G, Gangar SC, Jain AK, Agarwal C, Agarwal R.

Mol Carcinog. 2014 Mar;53(3):169-80. doi: 10.1002/mc.21959. Epub 2012 Oct 31.

20.

Fisetin Inhibits Osteoclast Differentiation via Downregulation of p38 and c-Fos-NFATc1 Signaling Pathways.

Choi SW, Son YJ, Yun JM, Kim SH.

Evid Based Complement Alternat Med. 2012;2012:810563. Epub 2012 Sep 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk